Endometrial cancer is the most common cancer of the female reproductive system in many high-income countries, and its incidence is rising in several regions. The disease is often diagnosed after symptoms such as abnormal uterine bleeding appear, which means that many patients already seek medical attention at a relatively early stage. However, symptoms can be mistaken for benign hormonal changes, particularly around menopause. Current diagnosis generally requires clinical assessment, imaging and tissue sampling from the uterus, procedures that can be uncomfortable, technically difficult or unsuitable for large-scale screening.

Urine offers an appealing alternative because it can be collected without surgery or specialized equipment. It contains a complex mixture of molecules filtered from the blood, released by cells lining the urinary tract and, in some cases, transported from distant tissues. Tumours can alter the concentration or structure of proteins, metabolites, nucleic acids and small membrane-bound particles in the body. Some of these cancer-associated signals may eventually reach the urine, where they could be measured using molecular assays.

The review by M. Dore, J. Cao, H. Baker-Rand and colleagues describes several classes of urinary biomarkers under investigation. Proteins are among the most extensively studied candidates. Tumour development can change the production of signalling proteins, enzymes and structural components, while inflammation around a tumour can alter the abundance of immune-related molecules. Measuring a single protein, however, is unlikely to provide sufficient accuracy on its own. Researchers are therefore exploring panels that combine multiple proteins and may distinguish cancer-associated patterns from changes caused by infection, kidney disease, menstruation or other conditions.

Another major area of research involves DNA and RNA. Cancer cells frequently acquire genetic mutations and chemical modifications known as epigenetic changes. One of the most promising signals is abnormal DNA methylation, in which chemical groups attach to DNA and alter gene activity without changing the underlying genetic sequence. Methylation patterns associated with endometrial cancer could potentially be detected in fragments of tumour-derived DNA found in urine. RNA molecules, including messenger RNA and regulatory microRNAs, may also reveal changes in gene expression. Because RNA is generally less stable than DNA, reliable collection and preservation methods are essential.

Urine also contains extracellular vesicles, microscopic membrane-enclosed particles released by cells. These vesicles can carry proteins, DNA fragments and RNA, protecting their contents from degradation as they travel through the body. Tumour-derived vesicles may contain molecular information that reflects the biology of the cancer more directly than freely circulating molecules. Researchers are developing methods to isolate and analyse them, but differences in laboratory protocols currently make results difficult to compare between studies. The small size and low abundance of some vesicles add further technical challenges.

Metabolomics provides a different route to detection. Tumours reprogramme their metabolism to support rapid growth, altering the way they process sugars, fats and amino acids. The resulting changes can produce distinctive patterns of small molecules in urine. Unlike a test aimed at one specific protein or mutation, metabolomic profiling can examine hundreds of chemical compounds simultaneously. Advanced mass spectrometry and nuclear magnetic resonance techniques have made this possible, although diet, medication, age, kidney function and the timing of collection can all influence the urinary metabolome.

The promise of urinary biomarkers lies not only in convenience but also in the possibility of combining different biological signals. A future test could integrate methylated DNA, proteins, metabolites and clinical information such as age, body mass index, bleeding patterns and genetic risk. Computational models, including machine-learning algorithms, may help identify combinations that are too subtle for conventional statistical analysis. Yet a highly accurate result in a small research cohort does not automatically translate into a dependable clinical test. Biomarkers must be validated in large, diverse populations that include people with benign uterine conditions and other cancers.

The review emphasizes that standardization will be crucial. Urine concentration varies substantially with hydration, and sample composition can change according to the time of day, collection method and interval between collection and processing. Laboratories may use different containers, preservatives, extraction techniques and detection platforms. Without agreed procedures, an apparent biomarker discovered in one study may fail to reproduce elsewhere. Researchers must also determine whether tests are intended to detect cancer in people with symptoms, identify individuals at elevated risk or monitor patients after treatment. Each purpose requires different levels of sensitivity, specificity and clinical evidence.

Urinary biomarkers are therefore not yet a replacement for tissue diagnosis, but they could become an important companion to existing approaches. A reliable urine test might help triage patients with abnormal bleeding, reduce unnecessary invasive procedures, support earlier referral and provide a practical method for monitoring recurrence. The field is moving toward multi-marker tests and more rigorous validation, but the decisive step will be demonstrating that these technologies improve patient outcomes in real-world healthcare. For now, urine-based detection remains a rapidly developing research strategy—one that could make endometrial cancer assessment more accessible if its biological complexity can be converted into a robust, clinically trustworthy signal.

Subject of Research: Urinary biomarkers for endometrial cancer detection

Article Title: Advances in urinary biomarkers for endometrial cancer detection

Article References: Dore, M., Cao, J., Baker-Rand, H. et al. “Advances in urinary biomarkers for endometrial cancer detection.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03579-8

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03579-8

Keywords: Endometrial cancer, urinary biomarkers, liquid biopsy, DNA methylation, extracellular vesicles, metabolomics, cancer detection, non-invasive diagnostics

Bladder cancer ranks among the most frequently diagnosed cancers worldwide, with NMIBC representing a significant subset of cases characterized by tumor confinement to the bladder’s inner lining without muscle invasion. Conventional cystoscopic examination and urine cytology, though standard, are invasive, expensive, and sometimes inconclusive, especially for low-grade lesions. Hence, the quest for minimally invasive, reliable biomarkers is imperative. Lipids, known for their crucial roles in cellular signaling, membrane structure, and energy homeostasis, have recently been implicated in cancer pathogenesis, opening the door for lipid-based diagnostic strategies.

The recent study harnessed the sophisticated technique of liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) to profile plasma lipid metabolites in a cohort of 214 individuals, including 106 NMIBC patients and 108 healthy controls. This technology enables unprecedented resolution and sensitivity in detecting subtle metabolic alterations associated with malignant transformation. By comparing lipidomes between groups, the researchers sought to decipher distinct biochemical signatures indicative of NMIBC presence and progression.

Findings revealed a pronounced disparity in plasma lipid profiles between NMIBC patients and healthy adults, underscoring the metabolic perturbations induced by bladder carcinogenesis. Notably, metabolites such as hydroxy fatty acids, O-linked triacylglycerols (O-TAG), O-linked lysophosphatidylglycerols (O-LPG), and various hydrocarbons were substantially enriched in the NMIBC group. These alterations suggest a profound remodeling of lipid metabolism in cancer cells, possibly reflecting adaptive mechanisms to support rapid proliferation and survival in the tumor microenvironment.

To translate these lipidomic insights into clinical practice, the authors developed predictive models leveraging select lipid panels. One such panel comprising phosphatidylethanolamines PE(14:1/20:0) and PE(18:2/16:0), alongside 19-methyl-heneicosanoic acid, demonstrated robust discriminatory power between NMIBC patients and controls. The model achieved an area under the curve (AUC) of 0.88 in training datasets, and maintained impressive validation performance with an AUC of 0.82. This level of accuracy rivals or surpasses many existing diagnostic modalities, signaling a potential paradigm shift.

Importantly, the model’s diagnostic capability extended effectively to low-grade NMIBC cases, which typically pose greater diagnostic ambiguity. An AUC of 0.81 for this subgroup highlights the panel’s sensitivity in detecting early-stage malignancies, a crucial factor for enabling timely interventions and improving patient prognoses. Additionally, the study explored grading differentiation by constructing a separate lipid panel capable of distinguishing between low- and high-grade NMIBC. This classifier attained an AUC of 0.815, with consistent cross-validation results, affirming its reproducibility and clinical utility.

These revelations support the notion that perturbations in lipid metabolism are not merely epiphenomena but contributory factors in bladder cancer pathophysiology. Lipid alterations may influence membrane fluidity, oxidative stress responses, and oncogenic signaling pathways. Thus, profiling these molecules offers dual benefits: serving as biomarkers for non-invasive diagnosis and providing insights into tumor biology that may guide therapeutic innovations.

Moreover, the use of plasma as a biofluid for lipidomic analysis highlights the feasibility of routine clinical application. Blood samples are relatively easy to obtain and process compared to invasive tissue biopsies, enhancing patient compliance and enabling longitudinal monitoring. Such monitoring could be vital for surveillance post-treatment, detecting recurrences early, and tailoring personalized management strategies based on lipidomic profiles.

The methodological rigor of the study, incorporating 10-fold cross-validation and leave-one-out validation techniques, strengthens the reliability of the results. These statistical approaches mitigate overfitting and affirm the generalizability of lipid biomarker panels across diverse patient populations. As the field advances, further large-scale multi-center studies will be essential to confirm these findings and optimize lipid panels for different demographic groups.

Integrating lipidomic data with other omics platforms, such as genomics and proteomics, could also amplify diagnostic precision and elucidate complex molecular interactions underpinning NMIBC. Systems biology approaches harnessing multi-modal data can enhance biomarker discovery and ultimately foster the development of targeted therapies aimed at lipid metabolism pathways disrupted in bladder cancer.

The study’s implications extend beyond NMIBC, suggesting that plasma lipidomics might be applicable to other urological malignancies and solid tumors where metabolic dysregulation is evident. Broadening this research may uncover universal or cancer-specific lipid signatures, paving the way for universal screening tools or tumor-type tailored diagnostics.

In conclusion, this pioneering research spotlights plasma lipidomics as a formidable approach to identify novel biomarkers capable of diagnosing and grading non-muscle invasive bladder cancer with high accuracy. The identified lipid profiles not only reflect disease presence but correlate with tumor aggressiveness, underscoring their value for early detection and clinical decision-making. As the medical community continues to grapple with the complexities of bladder cancer, lipid metabolite panels represent a promising leap toward more effective, non-invasive, and precise diagnostics fit for the demands of modern oncological practice.

Subject of Research: Non-muscle invasive bladder cancer (NMIBC) diagnosis and grading using plasma lipidomics.

Article Title: Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer.

Article References:
Zhao, Y., Ji, Z., Sun, W. et al. Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer. BMC Cancer 25, 1702 (2025). https://doi.org/10.1186/s12885-025-15019-6

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-15019-6